Publications from the European Academy of Allergy and Clinical Immunology (EAACI)
Haka J et al. 2019. Development of hypoallergenic variants of the major horse allergen Equ c 1 for immunotherapy by rational structure based engineering. Sci. Rep. 9(1):20148
Pali-Schöll I and and Jensen-Jarolim E. 2016. The concept of allergen-associated molecular patterns (AAMP). Curr. Opin. Immunol. 42:113–118
Mares-Mejía I et al. 2016. Structural insights into the IgE mediated responses induced by the allergens Hev b 8 and Zea m 12 in their dimeric forms. Sci. Rep. 6, 32552; doi: 10.1038/srep32552
Niemi MH et al. 2015. Dimerization of lipocalin allergens. Sci. Rep. 5, 13841; doi: 10.1038/srep13841
Levin M et al. 2014. Human IgE against the major allergen Bet v 1 – defining an epitope with limited cross-reactivity between different PR-10 family proteins. Clin Exp Allergy. 44(2):288-299
Jongejan L & van Ree R. 2014. Modified allergens and their potential to treat allergic disease. Curr Allergy Asthma Rep. 14(12):478
Kofler S et al. 2014. Stabilization of the dimeric birch pollen allergen Bet v 1 impacts its immunological properties. J Biol Chem. 289(1):540-51
Cox L et al. 2013. New directions in immunotherapy. Curr Allergy Asthma Rep. 13(2):178-95
Subbarayal B et al. 2013. Kinetics, cross-reactivity, and speciﬁcity of Bet v 1 -speciﬁc IgG4 antibodies induced by immunotherapy with birch pollen. Allergy 68(11):1377-86
Rouvinen J et al. 2010. Transient dimers of allergens. PLoS One. 5(2):e9037
Valenta R & Coffman R (Eds.) 2011. Vaccines against allergies. Curr Top Microbiol Immunol. 352:27-54.
Niemi M et al. 2008. Characterization and crystallization of a recombinant IgE Fab fragment in complex with the bovine beta-lactoglobulin allergen. Acta Crystallogr Sect F Struct Biol Cryst Commun. 64(Pt 1):25-28.
Niemi M et al. 2007. Molecular interactions between a recombinant IgE antibody and the beta-lactoglobulin allergen. Structure 15(11):1413-21.